Currax Pharmaceuticals has tapped Dr. Michael Kyle as SVP, chief medical officer. In the role, which reports to Currax president and CEO George Hampton, Kyle will oversee the company’s regulatory and medical affairs and clinical development/operations.
“Dr. Kyle brings a wealth of knowledge and industry expertise to Currax,” said Hampton in a statement. “Michael joins the organization at a critical juncture as we expand our efforts and support the launch of CX-101 for the indication of smoking cessation.”
Kyle previously served as head of development at Jiangsu HengRui Pharmaceuticals. Before that, he held a variety of roles at Pfizer.
